Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 6/20 | 0.84 |
| ▸ | KDM6A | O15550 | 5/20 | 0.84 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.84 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.84 |
| ▸ | KDM5C | P41229 | 3/20 | 0.84 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.84 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.84 |
| ▸ | KDM5A | P29375 | 3/20 | 0.84 |
| ▸ | KDM4A | O75164 | 2/20 | 0.84 |
| ▸ | KDM4B | O94953 | 2/20 | 0.84 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.84 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.84 |
| ▸ | MAOB | P27338 | 2/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.84 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.84 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.84 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.84 |
| ▸ | MAOA | P21397 | 1/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10157115 | 0.91 | KDM6B (1.00) | KDM6BKDM6AKDM5BKDM2BKDM5C | |
| SCHEMBL29353127 | 0.91 | KDM6B (1.00) | KDM6BKDM6AKDM5BKDM2BKDM5C | |
| SCHEMBL29371558 | 0.91 | KDM6B (1.00) | KDM6BKDM6AKDM5BKDM2BKDM5C | |
| SCHEMBL18159121 | 0.90 | KDM6B (0.85) | KDM6BKDM6AKDM5BKDM2BKDM5C | |
| SCHEMBL25183825 | 0.89 | HDAC1 (0.89) | KDM6BKDM6AKDM5BKDM2BKDM5C | |
| SCHEMBL21473967 | 0.89 | KDM6B (0.82) | KDM6BKDM6AKDM5BKDM2BKDM5C | |
| SCHEMBL29409168 | 0.88 | KDM6B (1.00) | KDM6BKDM6AKDM5BKDM2BKDM5C | |
| SCHEMBL29373519 | 0.88 | KDM6B (1.00) | KDM6BKDM6AKDM5BKDM2BKDM5C | |
| SCHEMBL14931829 | 0.88 | KDM6B (1.00) | KDM6BKDM6AKDM5BKDM2BKDM5C | |
| SCHEMBL25507239 | 0.88 | KDM6A (0.79) | KDM6BKDM6AKDM5BKDM2BKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150976-A1 | 4-Amino Pyrimidine Compounds for the Treatment of Cancer | UNIVERSITY OF ROCHESTER (US) | 2023-05-18 | — | — | US | disclosed |
| US-20200376146-A1 | NANOBIOLOGIC COMPOSITIONS FOR INHIBITING TRAINED IMMUNITY | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2020-12-03 | — | — | US | disclosed |
| US-20200376102-A1 | METHODS FOR INHIBITING TRAINED IMMUNITY WITH NANOBIOLOGIC COMPOSITIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2020-12-03 | — | — | US | disclosed |
| US-20160194718-A1 | Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators | DANA-FARBER CANCER INSTITUTE, INC. | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200376146-A1 | NANOBIOLOGIC COMPOSITIONS FOR INHIBITING TRAINED IMMUNITY | CD47, MYD88, TNF | KDM6B 1053/4885KDM6A 1124/4885KDM5B 830/4885 |
| US-20230150976-A1 | 4-Amino Pyrimidine Compounds for the Treatment of Cancer | KDM3B, KDM4D, KDM3A | KDM6B 10/4885KDM6A 20/4885KDM5B 15/4885 |
| US-20160194718-A1 | Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators | EZH2, BMI1, CBX3 | KDM6B 95/4885KDM6A 70/4885KDM5B 120/4885 |
| US-20200376102-A1 | METHODS FOR INHIBITING TRAINED IMMUNITY WITH NANOBIOLOGIC COMPOSITIONS | CD47, MYD88, IL2 | KDM6B 753/4885KDM6A 777/4885KDM5B 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.